Xilio Therapeutics (XLO) Cash from Operations (2020 - 2026)
Xilio Therapeutics (XLO) posted Cash from Operations of 22343000.0 for Q1 2026, down 1018.27% sequentially from 1998000.0 in Q4 2025, and down 177.1% YoY from 28978000.0 in Q1 2025.
Xilio Therapeutics (XLO) Cash from Operations (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 22343000.0 in Q1 2026.
- Quarterly Cash from Operations fell 177.1% year-over-year to 22343000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56313000.0 (down 366.86% YoY) and the FY2025 annual result came in at 4992000.0, up 72.84% from the prior year.
- Cash from Operations fell to 22343000.0 in Q1 2026 per XLO's latest filing, from 1998000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 28978000.0 in Q1 2025 and troughed at 25250000.0 in Q1 2023.
- A 5-year average of 11179764.71 and a median of 14477000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations surged 375.93% in 2025, then sank 177.1% in 2026.
- Over 5 years, Cash from Operations stood at 18223000.0 in 2022, then climbed by 26.32% to 13427000.0 in 2023, then declined by 5.44% to 14157000.0 in 2024, then jumped by 85.89% to 1998000.0 in 2025, then sank by 1018.27% to 22343000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 22343000.0, 1998000.0, and 17495000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -18.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.76 Mn |
| Jun 30, 2026 | -18.76 Mn |
| Mar 31, 2026 | -22.34 Mn |
| Mar 31, 2026 | -22.34 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Jun 30, 2025 | -14.48 Mn |
| Jun 30, 2025 | -14.48 Mn |
| Mar 31, 2025 | 28.98 Mn |
| Mar 31, 2025 | 28.98 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Sep 30, 2024 | -13.67 Mn |
| Sep 30, 2024 | -13.67 Mn |
| Jun 30, 2024 | 19.95 Mn |
| Jun 30, 2024 | 19.95 Mn |
| Mar 31, 2024 | -10.50 Mn |
| Mar 31, 2024 | -10.50 Mn |